NCT03417414View on ClinicalTrials.gov

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

UnknownOBSERVATIONAL
Enrollment

160

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
B Cell Lymphocytic LeukemiaB Cell Non-Hodgkin's Lymphoma
Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER